Naltrexone for Alcohol Use Disorder

"A meta-analysis that included 19 double-blind randomized clinical trials (RCTs; N = 2875) of at least 12 weeks’ duration reported that naltrexone 50 mg daily for AUD, compared with placebo, was associated with lower rates of return to heavy drinking (risk ratio [RR], 0.81 [95% CI, 0.72-0.90]), with a number needed to treat of 11.4 In this meta-analysis, compared with placebo, injectable naltrexone (2 RCTs; N = 467) was associated with a reduction in the percentage of drinking days over the 30-day treatment period (weighted mean difference, −4.99 [95% CI, −9.49 to −0.49]). Common adverse effects included self-limited nausea (range, 2.5%-57.6% with naltrexone, 0%-47.1% with placebo) and dizziness (range, 2.9%-34.8% with naltrexone, 0%-20.6% with placebo) with both naltrexone formulations,4 while injection site reactions occurred in up to 5.6% of patients with injectable naltrexone.5 Postmarketing studies have found naltrexone is safe in patients with Child-Pugh class A or B cirrhosis. As an opioid antagonist, naltrexone should not be used in patients concurrently taking opioids.5"

Source

Holt SR. Medications for Alcohol Use Disorder. JAMA. Published online August 19, 2026. doi:10.1001/jama.2026.10575